Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

ClinicalTrials.gov ID: NCT05665088

Public ClinicalTrials.gov record NCT05665088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of PRN Dosing of BXCL501 Over a 12 Week Treatment Period in Subjects With Agitation Associated With Dementia Who Require at Least Moderate To Full Assistance With Activities of Daily Living

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed \[PRN\]), for a maximum of 168 doses within a 12-week treatment period.

Study identification

NCT ID
NCT05665088
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
BioXcel Therapeutics Inc
Industry
Enrollment
13 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 5, 2022 (Actual)
Primary completion
Sep 11, 2023 (Actual)
Completion
Sep 11, 2023 (Actual)
Last update posted
Oct 1, 2026

2022 – 2023

United States locations

U.S. sites
7
U.S. states
5
U.S. cities
7
Facility City State ZIP Site status
BioXcel Clinical Research Site Los Alamitos California 90720 —
BioXcel Clinical Research Site Daytona Beach Florida 32117 —
BioXcel Clinical Research Site Maitland Florida 32751 —
BioXcel Clinical Research Site The Villages Florida 32162 —
BioXcel Clinical Research Site Marrero Louisiana 70072 —
BioXcel Clinical Research Site Springfield Massachusetts 01103 —
BioXcel Clinical Research Site Toms River New Jersey 08755 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05665088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 1, 2026 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05665088 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →